*********************************************************************************************************************************
UPDATE March 2017: two more arms added, one for MSS and other for MSI. Read post below, in this thread.
*********************************************************************************************************************************
Since years ago, we have been following on this forum immunotherapy trials that combine nivolumab (and PD-1) plus ipilimumab (anti CTLA-4). Very soon we learnt that the slots for MSS patients were few and, over the years, we also saw that it was showing activity only for those MSI tumours, anyway.
Recently this year, a trial that combines a PD-1 inhibitor with a MEK inhibitor, cobimetinib, showed success, finally, for MSS CRC: viewtopic.php?f=1&t=54825
Now, this past month, the big trial for nivo + ipi has updated its protocol to include that cobimetinib for the MSS arm:
A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142)
+ cobimetinib for the MSS arm:
https://clinicaltrials.gov/ct2/show/NCT02060188
Many locations, worldwide too.